Overview

The Nuvigil and Provigil Pregnancy Registry

Status:
Recruiting

Trial end date:
2027-01-31

Target enrollment:

Participant gender:

Summary

The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy.

Details

Lead Sponsor:

Teva Pharmaceutical Industries
Teva Pharmaceutical Industries, Ltd.

Collaborator:

United BioSource Corporation

Treatments:

Armodafinil
Modafinil